Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies

Journal of Allergy and Clinical Immunology: In Practice

Volumn 5, Issue 3, 2017, Pages 600-609

  Picard, Matthieu ^a   Galvão, Violeta Régnier ^b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Allergy; Challenge; Cytokine release; Desensitization; Hypersensitivity; IgE; IgG; Infusion reaction; Monoclonal antibody; Skin test

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CETUXIMAB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; OMALIZUMAB; PERTUZUMAB; RITUXIMAB; TOCILIZUMAB; TRASTUZUMAB; ALLERGEN; CYTOKINE;

ARTICLE; CLINICAL FEATURE; CYTOKINE RELEASE SYNDROME; DESENSITIZATION; DRUG CROSS REACTIVITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; HUMAN; HYPERSENSITIVITY; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOTHERAPY; INJECTION SITE REACTION; NONIMMEDIATE TYPE HYPERSENSITIVITY; PROVOCATION TEST; SERUM SICKNESS; SKIN TEST; ALGORITHM; ANIMAL; METABOLISM; PROCEDURES;

ALGORITHMS; ALLERGENS; ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; SKIN TESTS;

EID: 85009806805     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2016.12.001     Document Type: Article

References (100)

1. 1 Yin, L., Chen, X., Vicini, P., Rup, B., Hickling, T.P., Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cell Immunol 295 (2015), 118–126.
2. 2 Jani, M., Isaacs, J.D., Morgan, A.W., Wilson, A.G., Plant, D., Hyrich, K.L., et al. Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. Rheumatology (Oxford) 55 (2016), 2050–2055.
3. 3 International Nonproprietary Names (INN) for biological and biotechnological substances. Available from: http://www.who.int/medicines/services/inn/BioRev2011.pdf. Accessed September 6, 2016.
4. 4 Demoly, P., Adkinson, N.F., Brockow, K., Castells, M., Chiriac, A.M., Greenberger, P.A., et al. International Consensus on drug allergy. Allergy 69 (2014), 420–437.
5. 5 Jung, J.W., Kang, H.R., Lee, S.H., Cho, S.H., The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. Oncology 86 (2014), 127–134.
6. 6 Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., Engert, A., Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94 (1999), 2217–2224.
7. 7 Levin, A.S., Otani, I.M., Lax, T., Hochberg, E., Banerji, A., Reactions to rituximab in an outpatient infusion center: a 5-year review. J Allergy Clin Immunol Pract 5 (2017), 107–113.e1.
8. 8 Rituxan Prescribing Information. Available from: https://www.gene.com/download/pdf/rituxan_prescribing.pdf. Accessed October 10, 2016.
9. 9 Matucci, A., Pratesi, S., Petroni, G., Nencini, F., Virgili, G., Milla, M., et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 43 (2013), 659–664.
10. 10 Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Petroni, G., Cammelli, D., et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol 159 (2012), 321–326.
11. 11 Chung, C.H., Mirakhur, B., Chan, E., Le, Q.T., Berlin, J., Morse, M., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 (2008), 1109–1117.
12. 12 Brennan, P.J., Rodriguez Bouza, T., Hsu, F.I., Sloane, D.E., Castells, M.C., Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 124 (2009), 1259–1266.
13. 13 Sloane, D., Govindarajulu, U., Harrow-Mortelliti, J., Barry, W., Hsu, F.I., Hong, D., et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract 4 (2016), 497–504.
14. 14 Hesterberg, P.E., Banerji, A., Oren, E., Penson, R.T., Krasner, C.N., Seiden, M.V., et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 123 (2009), 1262–1267.e1.
15. 15 O'Meara, S., Nanda, K.S., Moss, A.C., Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 20 (2014), 1–6.
16. 16 Maneiro, J.R., Salgado, E., Gomez-Reino, J.J., Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 173 (2013), 1416–1428.
17. 17 van Vollenhoven, R.F., Emery, P., Bingham, C.O. III, Keystone, E.C., Fleischmann, R., Furst, D.E., et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37 (2010), 558–567.
18. 18 Finkelman, F.D., Khodoun, M.V., Strait, R., Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol 137 (2016), 1674–1680.
19. 19 van der Laken, C.J., Voskuyl, A.E., Roos, J.C., Stigter van Walsum, M., de Groot, E.R., Wolbink, G., et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66 (2007), 253–256.
20. 20 Bavbek, S., Ataman, S., Akinci, A., Castells, M., Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract 3 (2015), 629–632.
21. 21 Limb, S.L., Starke, P.R., Lee, C.E., Chowdhury, B.A., Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 120 (2007), 1378–1381.
22. 22 Karmacharya, P., Poudel, D.R., Pathak, R., Donato, A.A., Ghimire, S., Giri, S., et al. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum 45 (2015), 334–340.
23. 23 Lichtenstein, L., Ron, Y., Kivity, S., Ben-Horin, S., Israeli, E., Fraser, G.M., et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis 9 (2015), 806–815.
24. 24 Ally, M.R., Betteridge, J.D., Veerappan, G.R., Delayed hypersensitivity reaction with infliximab: unusual to occur after initial dose. Inflamm Bowel Dis 18 (2012), E1592–E1593.
25. 25 Cheifetz, A., Smedley, M., Martin, S., Reiter, M., Leone, G., Mayer, L., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 (2003), 1315–1324.
26. 26 Bulur, I., Keseroglu, H.O., Saracoglu, Z.N., Gonul, M., Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab. J Dermatol Case Rep 9 (2015), 12–14.
27. 27 Lowndes, S., Darby, A., Mead, G., Lister, A., Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 13 (2002), 1948–1950.
28. 28 Lin, W.L., Lin, W.C., Yang, J.Y., Chang, Y.C., Ho, H.C., Yang, L.C., et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 26 (2008), 2779–2780.
29. 29 Alvarez-Cuesta, E., Madrigal-Burgaleta, R., Angel-Pereira, D., Urena-Tavera, A., Zamora-Verduga, M., Lopez-Gonzalez, P., et al. Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization. Allergy 70 (2015), 784–794.
30. 30 Castells, M.C., Tennant, N.M., Sloane, D.E., Hsu, F.I., Barrett, N.A., Hong, D.I., et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122 (2008), 574–580.
31. 31 Kurz, A., Ikeda, T., Sessler, D.I., Larson, M.D., Bjorksten, A.R., Dechert, M., et al. Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold. Anesthesiology 86 (1997), 1046–1054.
32. 32 Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology, Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 105 (2010), 259–273.
33. 33 Remicade Prescribing Information. Available from: https://www.remicade.com/shared/product/remicade/prescribing-information.pdf. Accessed October 10, 2016.
34. 34 Cimzia Prescribing Information. Available from: http://www.cimzia.com/assets/pdf/Prescribing_Information.pdf. Accessed October 10, 2016.
35. 35 Humira Prescribing Information. Available from: http://www.rxabbvie.com/pdf/humira.pdf. Accessed October 10, 2016.
36. 36 Simponi Prescribing Information. Available from: http://www.simponi.com/shared/product/simponi/prescribing-information.pdf. Accessed October 10, 2016.
37. 37 Enbrel Prescribing Information. Available from: http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf. Accessed October 10, 2016.
38. 38 Mourad, A.A., Boktor, M.N., Yilmaz-Demirdag, Y., Bahna, S.L., Adverse reactions to infliximab and the outcome of desensitization. Ann Allergy Asthma Immunol 115 (2015), 143–146.
39. 39 Ducharme, J., Pelletier, C., Zacharias, R., The safety of infliximab infusions in the community setting. Can J Gastroenterol 24 (2010), 307–311.
40. 40 Choquette, D., Faraawi, R., Chow, A., Rodrigues, J., Bensen, W.J., Nantel, F., Incidence and management of infusion reactions to infliximab in a prospective real-world community registry. J Rheumatol 42 (2015), 1105–1111.
41. 41 Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Parronchi, P., Rossi, O., et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 65 (2010), 657–661.
42. 42 Freling, E., Peyrin-Biroulet, L., Poreaux, C., Morali, A., Waton, J., Schmutz, J.L., et al. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment. Eur J Gastroenterol Hepatol 27 (2015), 1200–1208.
43. 43 Vultaggio, A., Petroni, G., Pratesi, S., Nencini, F., Cammelli, D., Milla, M., et al. Circulating T cells to infliximab are mainly detectable in treated patients developing anti-drug antibodies and hypersensitivity reactions. Clin Exp Immunol 186 (2016), 364–372.
44. 44 Van den Brande, J.M., Braat, H., van den Brink, G.R., Versteeg, H.H., Bauer, C.A., Hoedemaeker, I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003), 1774–1785.
45. 45 Ben-Horin, S., Yavzori, M., Katz, L., Kopylov, U., Picard, O., Fudim, E., et al. The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 60 (2011), 41–48.
46. 46 Frederiksen, M.T., Ainsworth, M.A., Brynskov, J., Thomsen, O.O., Bendtzen, K., Steenholdt, C., Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis 20 (2014), 1714–1721.
47. 47 Steenholdt, C., Svenson, M., Bendtzen, K., Thomsen, O.O., Brynskov, J., Ainsworth, M.A., Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J Crohns Colitis 6 (2012), 108–111.
48. 48 Zeltser, R., Valle, L., Tanck, C., Holyst, M.M., Ritchlin, C., Gaspari, A.A., Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 137 (2001), 893–899.
49. 49 Feuerstein, J.D., Cheifetz, A.S., Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am 43 (2014), 543–563.
50. 50 Benucci, M., Manfredi, M., Demoly, P., Campi, P., Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy 63 (2008), 138–139.
51. 51 Paltiel, M., Gober, L.M., Deng, A., Mikdashi, J., Alexeeva, I., Saini, S.S., et al. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol 144 (2008), 1190–1194.
52. 52 Gamarra, R.M., McGraw, S.D., Drelichman, V.S., Maas, L.C., Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med 30 (2006), 41–44.
53. 53 Miheller, P., Muzes, G., Lakatos, G., Mihaly, E., Tulassay, Z., Repeated infliximab therapy after serum sickness-like reaction in Crohn's disease. J Emerg Med 32 (2007), 209–210 author reply 10.
54. 54 Cleynen, I., Van Moerkercke, W., Billiet, T., Vandecandelaere, P., Vande Casteele, N., Breynaert, C., et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med 164 (2016), 10–22.
55. 55 Vergara, G., Silvestre, J.F., Betlloch, I., Vela, P., Albares, M.P., Pascual, J.C., Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 138 (2002), 1258–1259.
56. 56 Mounach, A., Rezqi, A., Nouijai, A., Ghozlani, I., Achemlal, L., Maghraoui, A.E., et al. Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatol Int 33 (2013), 1351–1353.
57. 57 Ramos-Casals, M., Brito-Zeron, P., Munoz, S., Soria, N., Galiana, D., Bertolaccini, L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86 (2007), 242–251.
58. 58 Dilley, M.A., Lee, J.P., Platt, C.D., Broyles, A.D., Rituximab desensitization in pediatric patients: results of a case series. Pediatr Allergy Immunol Pulmonol 29 (2016), 91–94.
59. 59 Korycka-Wolowiec, A., Wolowiec, D., Robak, T., Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. Expert Opin Drug Saf 14 (2015), 1945–1959.
60. 60 Gazyva Prescribing Information. Available from: https://www.gene.com/download/pdf/gazyva_prescribing.pdf. Accessed October 14, 2016.
61. 61 Taylor, P.C., Quattrocchi, E., Mallett, S., Kurrasch, R., Petersen, J., Chang, D.J., Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70 (2011), 2119–2125.
62. 62 Arzerra Prescribing Information. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/arzerra.pdf. Accessed October 3, 2016.
63. 63 Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C.M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370 (2014), 1101–1110.
64. 64 Adcetris Prescribing Information. Available from: http://www.seattlegenetics.com/pdf/adcetris_USPI.pdf. Accessed October 11, 2016.
65. 65 O'Connell, A.E., Lee, J.P., Yee, C., Kesselheim, J., Dioun, A., Successful desensitization to brentuximab vedotin after anaphylaxis. Clin Lymphoma Myeloma Leuk 14 (2014), e73–e75.
66. 66 Arora, A., Bhatt, V.R., Liewer, S., Armitage, J.O., Bociek, R.G., Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma. Eur J Haematol 95 (2015), 361–364.
67. 67 DeVita, M.D., Evens, A.M., Rosen, S.T., Greenberger, P.A., Petrich, A.M., Multiple successful desensitizations to brentuximab vedotin: a case report and literature review. J Natl Compr Canc Netw 12 (2014), 465–471.
68. 68 Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363 (2010), 1812–1821.
69. 69 Herceptin Prescribing Information. Available from: https://www.gene.com/download/pdf/herceptin_prescribing.pdf. Accessed October 11, 2016.
70. 70 Thompson, L.M., Eckmann, K., Boster, B.L., Hess, K.R., Michaud, L.B., Esteva, F.J., et al. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist 19 (2014), 228–234.
71. 71 Cook-Bruns, N., Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61:Suppl 2 (2001), 58–66.
72. 72 Sheu, J., Hawryluk, E.B., Litsas, G., Thakuria, M., LeBoeuf, N.R., Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor. Clin Breast Cancer 15 (2015), e77–e81.
73. 73 Baselga, J., Cortes, J., Kim, S.B., Im, S.A., Hegg, R., Im, Y.H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366 (2012), 109–119.
74. 74 Genentech. Perjeta Prescribing Information. Available from: https://www.gene.com/download/pdf/perjeta_prescribing.pdf. Accessed October 8, 2016.
75. 75 Swain, S.M., Baselga, J., Kim, S.B., Ro, J., Semiglazov, V., Campone, M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372 (2015), 724–734.
76. 76 Gonzalez-de-Olano, D., Morgado, J.M., Juarez-Guerrero, R., Sanchez-Munoz, L., Letellez-Fernandez, J., Malon-Gimenez, D., et al. Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization. J Allergy Clin Immunol Pract 4 (2016), 338–340.
77. 77 Avastin Prescribing Information. Available from: http://www.gene.com/download/pdf/avastin_prescribing.pdf. Accessed October 4, 2016.
78. 78 Song, X., Long, S.R., Barber, B., Kassed, C.A., Healey, M., Jones, C., et al. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol 7 (2012), 56–65.
79. 79 Reidy, D.L., Chung, K.Y., Timoney, J.P., Park, V.J., Hollywood, E., Sklarin, N.T., et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 25 (2007), 2691–2695.
80. 80 O'Neil, B.H., Allen, R., Spigel, D.R., Stinchcombe, T.E., Moore, D.T., Berlin, J.D., et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25 (2007), 3644–3648.
81. 81 Commins, S.P., Satinover, S.M., Hosen, J., Mozena, J., Borish, L., Lewis, B.D., et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 123 (2009), 426–433.
82. 82 Commins, S.P., James, H.R., Kelly, L.A., Pochan, S.L., Workman, L.J., Perzanowski, M.S., et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-alpha-1,3-galactose. J Allergy Clin Immunol 127 (2011), 1286–1293.e6.
83. 83 Steinke, J.W., Platts-Mills, T.A., Commins, S.P., The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol 135 (2015), 589–596 quiz 97.
84. 84 Maier, S., Chung, C.H., Morse, M., Platts-Mills, T., Townes, L., Mukhopadhyay, P., et al. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer Med 4 (2015), 36–42.
85. 85 Garcia-Menaya, J.M., Cordobes-Duran, C., Gomez-Ulla, J., Zambonino, M.A., Mahecha, A.C., Chiarella, G.M., et al. Successful desensitization to cetuximab in a patient with a positive skin test to cetuximab and specific IgE to alpha-gal. J Investig Allergol Clin Immunol 26 (2016), 132–134.
86. 86 Jerath, M.R., Kwan, M., Kannarkat, M., Mirakhur, B., Carey, L., Valgus, J., et al. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol 123 (2009), 260–262.
87. 87 Langerak, A., River, G., Mitchell, E., Cheema, P., Shing, M., Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Clin Colorectal Cancer 8 (2009), 49–54.
88. 88 Saif, M.W., Peccerillo, J., Potter, V., Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol 63 (2009), 1017–1022.
89. 89 Actemra Prescribing Information. Available from: http://www.gene.com/download/pdf/actemra_prescribing.pdf. Accessed October 5, 2016.
90. 90 Rocchi, V., Puxeddu, I., Cataldo, G., Del Corso, I., Tavoni, A., Bazzichi, L., et al. Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis. Rheumatology (Oxford) 53 (2014), 1527–1529.
91. 91 Justet, A., Neukirch, C., Poubeau, P., Arrault, X., Borie, R., Dombret, M.C., et al. Successful rapid tocilizumab desensitization in a patient with Still disease. J Allergy Clin Immunol Pract 2 (2014), 631–632.
92. 92 Xolair Prescribing Information. Available from: https://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed October 11, 2016.
93. 93 Cox, L., Platts-Mills, T.A., Finegold, I., Schwartz, L.B., Simons, F.E., Wallace, D.V., American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120 (2007), 1373–1377.
94. 94 Lieberman, P.L., Umetsu, D.T., Carrigan, G.J., Rahmaoui, A., Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study. J Allergy Clin Immunol 138 (2016), 913–915.e2.
95. 95 Price, K.S., Hamilton, R.G., Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 28 (2007), 313–319.
96. 96 Cox, L., Lieberman, P., Wallace, D., Simons, F.E., Finegold, I., Platts-Mills, T., et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 128 (2011), 210–212.
97. 97 Owens, G., Petrov, A., Successful desensitization of three patients with hypersensitivity reactions to omalizumab. Curr Drug Saf 6 (2011), 339–342.
98. 98 Lieberman, P., Rahmaoui, A., Wong, D.A., The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol 105 (2010), 493–495.
99. 99 Jacquenet, S., Moneret-Vautrin, D.A., Bihain, B.E., Mammalian meat-induced anaphylaxis: clinical relevance of anti-galactose-alpha-1,3-galactose IgE confirmed by means of skin tests to cetuximab. J Allergy Clin Immunol 124 (2009), 603–605.
100. 100 Brown, S.G., Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114 (2004), 371–376.